Dupixent Was Supposed to Help.
It May Have Done the Opposite.

Contact us now to learn what you can do.

LEARN MORE

Dupixent Lawsuit

If you used Dupixent and were diagnosed with cutaneous T-cell lymphoma (CTCL), you may have legal options. We’re here to help.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Email List
Want to stay in the know about important information to help protect your future? Simply subscribe to our newsletter!

Dupixent Was Supposed to Help. It May Have Hidden Something Far More Dangerous.

When Big Pharma companies Regeneron and Sanofi released FDA-approved Dupixent (dupilumad) in March 2017, the injections claimed eczema sufferers would “FEEL THE HEAL,”1 and the brand topped the charts in a heartbeat.2 But there’s a BUT.

Eczema (atopic dermatitis/ AD) is deeply agonizing with such intense fiery itching that sufferers have a hard time not digging into lesions. In April 2024, after multiple Dupixent patients reported developing cutaneous T-cell lymphoma (CTCL/ cancer of the white blood cells), researchers began to formally investigate a possible link and found a 4x higher incidence of T-cell cancer progressing among Dupixent users.3

If you or a loved one used Dupixent and developed cutaneous T-cell lymphoma/ CTCL, please contact us about participating in a Dupixent lawsuit.

CONTACT US

“As dupilumab becomes more commonplace in the treatment of AD [eczema] and atopic disease, we anticipate seeing a greater number of cases of unmasked CTCL in patients initially diagnosed with atypical AD.”4

– National Institutes of Health

What Is Dupixent and What Is It Prescribed For?

Dupixent (dupilumab) is a prescription drug co-developed by Sanofi and Regeneron Pharmaceuticals, FDA-approved in 2017. It is administered via injection every 2-4 weeks, purposed to block two immune-system proteins that accelerate chronic inflammation.

Upon release, brand name “Dupixent” fast became one of the most widespread drugs prescribed in the US, earning off-the-charts profits for both companies.

Dupixent is prescribed to treat:

  • Eczema (atopic dermatitis/ AD)
  • Eosinophilic esophagitis/ EoE (chronic immune system disease where white blood cells accumulate in the esophagus.5
  • Chronic rhinosinusitis with nasal polyps (a long-term condition that keeps mucus from draining, making the nose stuffy, breathing difficult, and eyes/ face swollen or tender).6
  • Prurigo nodularis (chronic skin condition that causes itchy bumps on the skin, usually with eczema or psoriasis, but not always).7
  • Allergic fungal rhinosinusitis/ AFRS (type of fungal infection in the sinuses) –approved for Dupixent treatment in February 20268
  • Chronic spontaneous urticaria (chronic hives) – approved for Dupixent treatment in April 2025. 9
  • Bullous pemphigoid (rare skin condition that causes large fluid-filled blisters, often appearing on the skin near creases, such as the upper thighs and armpits) –approved for Dupixent treatment in June 2025.10

What Are the Problems with Dupixent?

From January 2017 to the end of 2023, 181,575 unique incidences of dupilumab-related adverse events (AEs) were reported to the FDA, with 606 being for a neoplasm – abnormal cells rapidly dividing. Reports from Dupixent users were 4x higher, but the FDA didn’t put Dupixent on an alert list until late 2024.11

A JAAD/ Journal of the American Academy of Dermatology study published by the NIH in March 2020 followed four patients with initially diagnosed eczema, but who were eventually re-diagnosed with T-cell lymphoma after Dupixent treatments. Three patients were already diagnosed with CTCL before using Dupixent but were also diagnosed with Sézary syndrome during treatment, and two of them died from progressing T-cell lymphoma.12

A 2022 case series published in JAAD described multiple cases where CTCL emerged or rapidly progressed after eczema patients began Dupixent therapy – sometimes within a year. This data was available to manufacturers years before the FDA released the 2024 safety alert.13

Meanwhile, other similar skin or inflammatory conditions treated with Dupixent would prove to mimic early-stage CTCL, masking and potentially speeding the cancer but delaying its correct diagnosis, including: Erythroderma (like a 3rd-degree sunburn) and Sézary syndrome (mimicking both T-cell lymphoma and leukemia).14, 15

Has the FDA Taken Action?

Hmm. Despite the fact that the FDA formally flagged Dupixent as a potential health risk in August 2024 and put it on the FDA Potential Signals of Serious Risks list in October 2025, the agency still maintained as of April 2026 that the drug’s benefits outweigh its risks; and it continues to approve injections for treatment of additional conditions.16

And, as of early 2026, the FDA has still not required Regeneron and Sanofi to update Dupixent labels reflecting a potentially 4x higher risk of CTCL. As it debates whether to require new warning labels, the drug is still on the market amid lawsuits mounting in every state – all consolidated into an MDL/ multidistrict litigation in Georgia.17

CONTACT US TODAY

What Is the Dupixent Lawsuit About?

Regeneron and Sanofi are accused by patients who underwent Dupixent treatment for moderate-to-severe eczema, psoriasis, asthma, and other inflammatory disorders of marketing a drug that can cause and exacerbate progression of cancer, specifically T-cell lymphoma.

Plaintiffs in the Dupixent lawsuit say makers were aware of the cancer link and increased risk but failed to warn patients or their doctors and failed to demand that labels be revised to appropriately warn of CTCL.

As of March 2026, Dupixent’s FDA-approved label still doesn’t warn patients or doctors about the risk for CTCL, despite the fact that the FDA has received hundreds of reports of CTCL from Dupixent users since 2017 and even placed the drug on its Potential Signals of Serious Risks list.

A Case for Women Has Been Fighting Big Pharma for Years — and We’re Not Stopping Now.

We can’t believe that the FDA seems more beholden to Big Pharma than the health of American individuals. Tragically, this case is yet another example.

Since 2015, we’ve been passionately up to our ears championing landmark lawsuits, going up against giant misrepresentation of dangerous drugs and medical devices. Here is a handful of those pivotal cases:

If you or a loved one developed cutaneous T-cell lymphoma cancer after being treated with Dupixent, we want to help. ACFW exists to empower women and families. When you’ve been hurt, we will stand with you.

This isn’t right, plain and simple, and we’re here to help you prove it. The Dupixent lawyers we work with work on contingency so you owe them nothing unless they win a financial award on your behalf.

Contact us for life-altering legal help, 24/7/365.

LET US HELP

Sources

  1. Dupixent commercial, YouTube, January 7, 2026.
  2. Carly Helfand, “The top 10 drug launches of 2017 – #2 Dupixent,” Fierce Pharma, January 30, 2017.
  3. Iraj Hasan, Lauren Parsons, Sabrina Duran, Zachary Zinn, “Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study,” JAAD/ Journal of the American Academy of Dermatology, August 2024.
  4. Maria L Espinosa, Morgan T Nguyen, Amaia Saenz Aguirre, Maria Estele Martinez-Escala, Jane Kim, Christina J Walker, David S Pontes, Jonathan I Silverberg, Jaehyuk Choi, Barbara Pro, Laura B Pincus, Joan Buitart, Xiaolong Alan Zhou, “Progression of Cutaneous T-Cell Lymphoma after dupilumab: Case review of 7 patients,” NIH/ National Library of Medicine, March 27, 2020.
  5. Staff, “Chronic rhinosinusitis,” Mayo Clinic, current.  
  6. Staff, “Eosinophilic esophagitis (EoE),” Mayo Clinic, current.
  7. Staff, “Prurigo nodularis,” Cleveland Clinic, current.
  8. Staff, “Allergic fungal rhinosinusitis (AFRS),” Cedars Sinai, current.
  9. Staff, “Chronic spontaneous urticaria,” Cleveland Clinic, current
  10. Staff, “Bullous pemphigoid,” Mayo Clinic, current.
  11. Jenna Mandel, Jaanvi Mehta, Ramsay Hafer, Mahaa Ayub, Faria Nusrat, Henry Yang, Pierluigi Porcu, Neda Nikbakht, “Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis,” Wiley Online Library, August 14, 2024.
  12. Javier S. Cabrera-Perez MD, PhD, Vincent J. Carey PhD, Oreofe O. Odejide MD, MPH, Sonal Singh MD, MPG, Thomas S. Kupper MD, Shiv S. Pillai MBBS, PhD, Scott T. Weiss MD, MS, Ayobami Akenroye MBChB, PhD, “Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmaking or progression with dupilumab therapy,” ScienceDirect, May 2025.
  13. Marie Beylot-Barry, Delphine Staumont-Salle, “Cutaneous T-Cell Lymphoma and Dupilumab Use: A Multifactorial and Complex Story,” JID/ Journal of Investigative Dermatology, January 2025.
  14. Staff, “Sézary syndrome,” Mayo Clinic, current.
  15. Staff, “July-September 2021 | Potential signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS), US Food & Drug Administration, August 29, 2025.
  16. Joyani Das, PhD, “Dupixent: FDA Approves First and Only Medicine for Allergic Fungal Rhinosinusitis in Adults and Children Ages 6 Years and Older,” WebMD, February 25, 2026.
  17. Staff, “Dupixent Lawsuits: Allegations, Safety Steps and Legal Options,” Consumer Notice, December 22, 2025.